A Trial of Varenicline for E-cigarette Cessation
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorYale University
About this trial
This is randomized, placebo-controlled clinical trial in treatment-seeking adults who report regular e-cigarette use to test the hypothesis that varenicline is efficacious for quitting e-cigarettes.
Eligibility criteria
Qualifiers
report daily use of an e-cigarette containing nicotine
live in Connecticut or South Carolina
Disqualifiers
regular use of other tobacco products besides e-cigarettes
medical contraindications for varenicline use
current treatment for tobacco cessation
lack proficiency in English
Trial design
Treatments tested in this trial
- Varenicline 1mg BID
- Placebo
Treatment groups
326 Participants
are divided into 2 treatment groupsLocations
2Yale Cancer Center/Smilow Cancer Hospital at Yale-New Haven06520, New HavenConnecticut, United States
Hollings Cancer Center at MUSC (HCC)29425, CharlestonSouth Carolina, United States
Sponsors and collaborators
Yale University
Lead sponsor
National Cancer Institute (NCI)
Collaborator
Source ClinicalTrials.gov